KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1343-1345

  Gutiérrez, Cristina ^a   Rodriguez, Javier ^a   Patiño García, Ana ^a   García Foncillas, Jesús ^b   Salgado, Josefa ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Jimenez Diaz Foundation   (Spain)

Author keywords

Circulating tumor cells; Inmunomagnetic labeling; KRAS gene; Metastatic colorectal cancer; Peripheral blood

Indexed keywords

CD45 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE;

ARTICLE; CELL ADHESION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA PURIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION;

EID: 84884471017     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1544     Document Type: Article

References (16)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and FormanD: Global cancer statistics. CA Cancer J Clin61: 69-90, 2011.
2. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096, 2009.
3. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA and Eckhardt SG: KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27: 1130-1136, 2009.
4. Sartore-Bianchi A, Bencardino K, Cassingena A, et al: Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treat Rev 36 Suppl 3: S1-S5, 2010.
5. De Roock W, De Vriendt V, Normanno N, Ciardiello F and TejparS: KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12: 594-603, 2011.
6. Artale S, Sartore-Bianchi A, Veronese SM, et al: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26: 4217-4219, 2008.
7. Kosakowska EA, Stec R, Charkiewicz R, Skoczek M and Chyczewski L: Molecular differences in the KRAS gene mutation between a primary tumor and related metastatic sites-case report and a literature review. Folia Histochem Cytobiol 48: 597-602, 2010.
8. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH and Gabbert HE: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16: 790-799, 2010.
9. Ashworth T: A case of cancer in which cells similar to those in the tumours were seen in blood after death. Aust Med J14: 146-149, 1869.
10. Gerges N, Rak J and Jabado N: New technologies for the detection of circulating tumour cells. Br Med Bull 94: 49-64, 2010.
11. Alunni-Fabbroni M and Sandri MT: Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods 50: 289-297, 2010.
12. Lustberg M, Jatana KR, Zborowski M and Chalmers JJ: Emerging technologies for CTC detection based on depletion of normal cells. Recent Results Cancer Res 195: 97-110, 2012.
13. Baas JM, Krens LL, Guchelaar HJ, Morreau H and GelderblomH: Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: A review. Oncologist 16: 1239-1249, 2011.
14. Bossard C, Küry S, Jamet P, et al: Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas. J Clin Pathol 65: 466-469, 2012.
15. Bouchahda M, Karaboué A, Saffroy R, et al: Acquired KRAS mutations during progression of colorectal cancer metastases: Possible implications for therapy and prognosis. Cancer Chemother Pharmacol 66: 605-609, 2010.
16. Wicha MS and Hayes DF: Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol29: 1508-1511, 2011.